Target
STAT3
5 abstracts
Abstract
Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer.Org: Emory Winship Cancer Institue, Emory Winship Cancer Institute,
Abstract
PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC).Org: Stathmi, Inc.,
Abstract
Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.Org: University of Texas MD Anderson Cancer Center, Houston, TX, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan, The University of Texas M.D. Anderson Cancer Center, UT Health San Antonio, MD Anderson Cancer Center,
Abstract
GLS in Philadelphia-negative and JAK2 V617F-driven myeloproliferative neoplasms (MPNs).Org: University of Chicago, Univeristy of Chicago, Policlinico San Matteo, University of Pavia, Fondazione I.R.C.C.S. Policlinico San Matteo,
Abstract
Comprehension characterization of prostate cancer cell lines identified JAK-STAT3 signaling in lineage-switched non-neuroendocrine cells.Org: Department of Biochemistry and Molecular Biology, FWCC LSU Health Shreveport, LSU Health Shreveport, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,